WO1999043815A3 - Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof - Google Patents
Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof Download PDFInfo
- Publication number
- WO1999043815A3 WO1999043815A3 PCT/CA1999/000178 CA9900178W WO9943815A3 WO 1999043815 A3 WO1999043815 A3 WO 1999043815A3 CA 9900178 W CA9900178 W CA 9900178W WO 9943815 A3 WO9943815 A3 WO 9943815A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- human monoclonal
- recognizing
- oligospecifically
- methods
- monoclonal antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002322003A CA2322003A1 (en) | 1998-02-27 | 1999-02-26 | Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof |
AU32427/99A AU3242799A (en) | 1998-02-27 | 1999-02-26 | Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof |
EP99936093A EP1056861A2 (en) | 1998-02-27 | 1999-02-26 | Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7620098P | 1998-02-27 | 1998-02-27 | |
US60/076,200 | 1998-02-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999043815A2 WO1999043815A2 (en) | 1999-09-02 |
WO1999043815A3 true WO1999043815A3 (en) | 1999-11-25 |
Family
ID=22130549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA1999/000178 WO1999043815A2 (en) | 1998-02-27 | 1999-02-26 | Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1056861A2 (en) |
AU (1) | AU3242799A (en) |
CA (1) | CA2322003A1 (en) |
WO (1) | WO1999043815A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2441863A1 (en) * | 2001-03-29 | 2002-10-10 | Kenya Shitara | Drugs containing genetically modified antibody against ganglioside gd3 |
CA2498778A1 (en) | 2002-09-11 | 2004-03-25 | Shantha West, Inc. | Antibodies that recognize hyperproliferative cells and methods of making and using same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0480440A1 (en) * | 1990-10-11 | 1992-04-15 | Roche Diagnostics GmbH | Monoclonal antibody against melanoma |
EP0492409A1 (en) * | 1990-12-18 | 1992-07-01 | Ishihara Sangyo Kaisha, Ltd. | Human monoclonal antibody |
WO1994019457A1 (en) * | 1993-02-26 | 1994-09-01 | The Regents Of The University Of California | Human b-lymphoblastoid cell line secreting anti-ganglioside antibody |
-
1999
- 1999-02-26 CA CA002322003A patent/CA2322003A1/en not_active Abandoned
- 1999-02-26 EP EP99936093A patent/EP1056861A2/en not_active Withdrawn
- 1999-02-26 AU AU32427/99A patent/AU3242799A/en not_active Abandoned
- 1999-02-26 WO PCT/CA1999/000178 patent/WO1999043815A2/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0480440A1 (en) * | 1990-10-11 | 1992-04-15 | Roche Diagnostics GmbH | Monoclonal antibody against melanoma |
EP0492409A1 (en) * | 1990-12-18 | 1992-07-01 | Ishihara Sangyo Kaisha, Ltd. | Human monoclonal antibody |
WO1994019457A1 (en) * | 1993-02-26 | 1994-09-01 | The Regents Of The University Of California | Human b-lymphoblastoid cell line secreting anti-ganglioside antibody |
Non-Patent Citations (5)
Title |
---|
H. YAMAGUCHI ET AL.: "Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 87, no. 9, May 1990 (1990-05-01), Washington, DC, USA, pages 3333 - 3337, XP002116959 * |
K. FURUKAWA ET AL.: "Two human monoclonal antibodies reacting with the major gangliosides of human melanomas and comparison with corresponding mouse monoclonal antibodies.", CANCER RESEARCH, vol. 49, no. 1, 1 January 1989 (1989-01-01), Baltimore, MD, USA, pages 191 - 196, XP000608629 * |
M. ALFONSO ET AL.: "Generation of human monoclonal antibodies against ganglioside antigens and their applications in the diagnosis and therapy of cancer.", ACTA ONCOLOGICA, vol. 35, no. 3, 1996, Stockholm, Sweden, pages 287 - 295, XP002116960 * |
S. MUKERJEE ET AL.: "Characterization of human IgG1 monoclonal antibody against gangliosides expressed on tumor cells.", HYBRIDOMA, vol. 17, no. 2, April 1998 (1998-04-01), New York, NY, USA, pages 133 - 142, XP002116961 * |
Z. ABDEL-WAHAB ET AL.: "Cell surface reactive human monoclonal antibody directed to human melanoma-associated gangliosides.", MELANOMA RESEARCH, vol. 3, no. 6, December 1993 (1993-12-01), Oxford, GB, pages 415 - 423, XP000608631 * |
Also Published As
Publication number | Publication date |
---|---|
WO1999043815A2 (en) | 1999-09-02 |
CA2322003A1 (en) | 1999-09-02 |
EP1056861A2 (en) | 2000-12-06 |
AU3242799A (en) | 1999-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0200537A2 (en) | Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases | |
WO2004001381A3 (en) | Novel raag10 cell surface target and a family of antibodies recognizing that target | |
MD1374G2 (en) | Monoclonal immunostimulatin antibodies, method of obtaining thereof, cell lines, method of disease treatment and pharmaceutical composition | |
WO2004032857A8 (en) | Antibody therapy | |
AU6266899A (en) | Methods for producing human tumor antigen specific antibodies | |
DE69734109D1 (en) | Humanization of anti-carcinoembryonic antigen anti-idiotypic antibodies and their use as a tumor vaccine and for labeling | |
WO2000073801A3 (en) | Breast, gastric and prostate cancer associated antigens and uses therefor | |
WO2002006317A3 (en) | Compositions and methods for the therapy and diagnosis of ovarian cancer | |
AU2190997A (en) | Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation | |
ES2176574T3 (en) | USE OF BI AND TRIESPECIFIC ANTIBODIES FOR INDUCTION OF TUMOR IMMUNITY. | |
IE890720L (en) | Improvements relating to antigens | |
WO2000036107A3 (en) | Compositions and methods for therapy and diagnosis of ovarian cancer | |
WO2002016413A3 (en) | Cripto tumour polypeptide | |
TR200001253T2 (en) | Tumor-specific antigens | |
IL126803A0 (en) | Method and composition for reconforming multi-epitopic antigens to initiate an immune response | |
WO2004043239A3 (en) | Antigen pipa and antibodies that bind thereto | |
SG146644A1 (en) | Kid3 and kid3 antibodies that bind thereto | |
WO2002078516A3 (en) | Compositions and methods for the therapy and diagnosis of cancer | |
EP0352722A3 (en) | Adenocarcinoma antigen binding methods and reagents | |
AU2829889A (en) | Sf-25 colon adenocarcinoma antigen, and antibodies which recognize this antigen | |
WO2000032635A3 (en) | Tumor specific human monoclonal antibodies and methods of use | |
WO1999043815A3 (en) | Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof | |
WO2001036485A3 (en) | Recombinant monoclonal antibodies recognizing antigen ior c2 and the use thereof in the diagnosis and treatment of colorectal tumors | |
AU2070688A (en) | Antigen recognized by mca 16-88 | |
AU2002326318A1 (en) | Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 32427/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2322003 Country of ref document: CA Kind code of ref document: A Ref document number: 2322003 |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09648624 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999936093 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999936093 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999936093 Country of ref document: EP |